| |
Unleash the Full Potential of Your Data! Our BioELN Solution maximizes your success with efficient resources and knowledge management. Transform data into discoveries with Signals Notebook. Learn more in our white paper.
|
|
Today's Big NewsMay 8, 2023 |
|
Wednesday, May 17, 2023 2:00pm ET / 11:00am PT Join this webinar to learn more about the opprtunity medical affairs teams and medical science liaisons (MSLs) have to engage with HCPs in clinical discussions and bridge care gaps by providing crucial insights into evidence-based medicine. Register now to learn more.
|
|
| By Max Bayer The historically slow pace of biotech IPOs in 2022 has kept up so far this year, with just six companies hitting Wall Street so far. |
|
|
|
By Kevin Dunleavy Pfizer and AstraZeneca have retained their crowns as the most transformative companies in the industry, according to IDEA Pharma. On IDEA’s annual Innovation and Invention Index, Pfizer and AZ held the top spots for the second straight year. |
By Conor Hale The FDA said it has significant concerns of bacteria within the liquid solution provided with the companies’ Pilot at-home kits, including about 500,000 tests shipped to CVS Health pharmacies and 16,000 tests stocked with Amazon. |
By Nick Paul Taylor Eisai is joining the HER2 antibody-drug conjugate gold rush. After seeing AstraZeneca and Daiichi Sankyo validate the approach, Eiasi has struck a $2 billion biobucks deal with Bliss Biopharmaceutical for a spot alongside BioNTech in the chasing pack. |
|
Tuesday, May 23, 2023 | 2pm ET / 11am PT Clinical trials are complex, time-consuming, and costly. But what if you could use simulation to guide your decisions and optimize your trial design? In this webinar, we'll discuss the power of simulation-guided trial design (SGTD) and explain its benefits to clinical development strategies. Register now to join us.
|
|
By Fraiser Kansteiner Ahead of a long-awaited advisory committee meeting on Perrigo’s over-the-counter birth control prospect Opill, the FDA says many big questions remain. |
By Andrea Park As Twist Bioscience aims to untangle its operations and focus only on its most potentially profitable work, the synthetic DNA maker is cutting down its workforce. |
By Max Bayer Exelixis’ board of directors is waving the white flag after a third director targeted by activist investor Farallon Capital Management announced he wouldn’t stand for reelection. |
By Zoey Becker After raking in billions with its Pfizer-partnered COVID-19 vaccine, BioNTech is now forced to look for growth elsewhere. |
By Andrea Park Baxter is saying bye-bye, biopharma. |
By Nick Paul Taylor Amgen has ended its alliance with Entera Bio. The partners entered into a $270 million, three-molecule deal in 2018 but have agreed to scuttle the collaboration before reaching any major milestones. |
By Conor Hale The time has come for Tempus to secure its first premarket approval from the FDA, with a green light for a companion diagnostic to help profile the underlying genetic makeup of solid tumors. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we're continuing our miniseries on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
|
|---|
|
|
|
Thursday, May 25, 2023 | 10:00am ET / 7:00am PT Join the webinar and discover our MVA technology platform and explore the advantages for development and manufacturing of multiple vaccines and cell and gene therapeutics. Register now.
|
|
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperHow can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
